06 Aug 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Current president of CSL Behring, Mr Paul Perreault, will be the new CEO of the firm after Dr Brian McNamee steps down in July 2013. Dr Brian McNamee will leave CSL in July 2013 after being at the helm of the company for 23 years.
Mr Perreault joined the company in 2004 as part of the Aventis Behring acquisition. He has been a highly effective global leader in his current role carrying responsibility for the CSL Group's international manufacturing and commercial operations across 26 countries which comprise over 85 percent of CSL Group revenues.
He previously held the role of executive vice president for commercial operations during a period of exceptional revenue growth and expansion into new markets and his early career spanned both commercial and operational leadership. He will bring to the role of CEO strong leadership qualities and more than 30 years experience in the healthcare and biopharmaceutical industry.
Professor John Shine, chairman, CSL, while speaking about the appointment, said that, "Paul was selected after consideration of a strong field of well-qualified candidates. The process has reconfirmed the board's confidence in the quality and depth of CSL's global management. Paul brings tremendous leadership capability to the role, together with deep experience in the day to day management of CSL's global operations. He has been closely involved in the development of the current strategy and we are confident he will continue the trajectory of CSL's growth and outstanding performance."